Compugen (NASDAQ:CGEN – Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect Compugen to post earnings of ($0.08) per share and revenue of $1.28 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.
Compugen Trading Up 2.1%
NASDAQ:CGEN opened at $1.96 on Friday. The firm has a market cap of $185.32 million, a PE ratio of 5.16 and a beta of 2.85. The stock has a fifty day moving average price of $2.25 and a 200 day moving average price of $2.29. Compugen has a 12-month low of $1.43 and a 12-month high of $3.23.
Analyst Upgrades and Downgrades
CGEN has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Compugen in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $4.00 price objective on shares of Compugen in a research report on Monday, October 12th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $5.00.
About Compugen
Compugen Ltd. (NASDAQ: CGEN) is an Israeli clinical-stage biotechnology company focused on discovering and developing novel therapeutic and drug targets for cancer and other diseases. The company uses computational biology and artificial intelligence-based approaches to identify previously unrecognized biological mechanisms and translate them into potential medicines.
Compugen’s research has primarily centered on immuno-oncology, with an emphasis on regulating immune responses within the tumor microenvironment.
Read More
- Five stocks we like better than Compugen
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.
